A coastal research digest / two GHRH analogs
Sermorelin vs Tesamorelin: Two GHRH Analogs Compared
Both engage the same pituitary receptor; the difference is durability and where each was studied. One is the native fragment, the other a stabilized analog that has carried the adult cognition and body-fat trials.
The short version
Set sermorelin vs tesamorelin side by side and the contrast is durability, not direction. Both are GHRH analogs — both press the same "make growth hormone" button on the pituitary. Sermorelin is the plain natural fragment, GHRH(1-29), and it clears from the blood in about ten to twelve minutes. Tesamorelin is a chemically stabilized version that lasts longer in the body, which is why it, not sermorelin, was the analog used in the larger adult studies of thinking and body fat. So they share a mechanism; they differ in how long they act and which trials they appear in.
Structure and Duration: Native Fragment vs Stabilized Analog
Sermorelin is native GHRH(1-29) — the unmodified 29-amino-acid fragment — with a short plasma half-life on the order of 10-12 minutes after intravenous dosing; a single dose still keeps growth hormone elevated for roughly 3 hours despite that rapid clearance [3]. Tesamorelin is a stabilized synthetic GHRH analog, modified to resist degradation and last longer in circulation; it is approved (for HIV-associated lipodystrophy) and is frequently studied alongside GHRH(1-29) in body-composition and cognition research [6].
The practical line between them is duration of action and study setting. Both bind the GHRH receptor on pituitary somatotrophs and drive the same upstream, feedback-preserving growth-hormone release. Sermorelin's brevity is exactly what motivated the family of longer-acting analogs in the first place — the structural fix that buys more sustained exposure. Tesamorelin's stability is why it, rather than the native fragment, anchors several of the larger adult RCTs.
The Comparison at a Glance
It helps to lay the two side by side. On structure, sermorelin is the native, unmodified GHRH(1-29) fragment, while tesamorelin is a chemically stabilized GHRH analog engineered to resist enzymatic breakdown. On durability, sermorelin's plasma half-life sits near 10-12 minutes [3], whereas the stabilization that defines tesamorelin is precisely the trait that extends its circulating exposure beyond the native peptide [6]. On regulatory standing, sermorelin is a formerly FDA-approved compound now prepared by compounding pharmacies, while tesamorelin is a currently approved analog with a single, narrow approved indication (HIV-associated lipodystrophy) [6].
On the evidence base, the difference is the most consequential for a reader. Native GHRH(1-29) carries the historical pediatric efficacy trial [2] and the older-men aging-axis study [5]; the stabilized analog carries the larger adult cognition-and-body-composition RCT that reported a favorable cognition effect, IGF-1 +117%, and body fat -7.4% [10]. On mechanism, though, they are the same story: one GHRH receptor, one upstream, feedback-preserving release of the body's own pulsatile growth hormone. The contrast is durability and study setting, not pathway.
What Carries Over Between Them, and What Does Not
The mechanism carries over cleanly. Because both compounds engage the GHRH receptor on the pituitary and lean on the same somatostatin and IGF-1 feedback, the qualitative picture — stimulated, pulsatile, feedback-regulated growth-hormone release rather than injected hormone — applies to both [4][6]. A reader can reason from one to the other at the level of "how the molecule talks to the pituitary."
What does not carry over is the trial data. Tesamorelin's specific quantitative results were generated with tesamorelin, in tesamorelin's trial populations, at tesamorelin's sustained exposure — they are not native sermorelin's numbers, and attributing the cognition or body-fat figures to sermorelin would misstate the record [10]. This is the single most common error in popular sermorelin-versus-tesamorelin summaries, and it is the reason this page keeps the attributions explicit. Shared receptor, shared upstream logic; separate molecules, separate evidence.
Can GHRH Improve Cognition in Older Adults?
In a randomized, double-blind, placebo-controlled trial of 152 older adults (66 with mild cognitive impairment), 20 weeks of a daily GHRH analog — tesamorelin, 1 mg before bedtime — had a favorable effect on cognition (P=0.03), raised IGF-1 by 117% within the physiologic range, and cut body fat 7.4%, with adverse events mild (the SMART trial, NCT00257712) [10]. In aged rodents, chronic [D-Ala2]-GHRH attenuated age-related spatial-memory deficits [12]. The cognition signal here is the analog's; native sermorelin was not the agent in this RCT.
This is the clearest reason the comparison matters. The most-cited adult cognition and body-composition data in this space were generated with the stabilized analog, not native GHRH(1-29). Reading the GHRH and cognition in older adults literature, the honest attribution is to tesamorelin; sermorelin shares the receptor and the upstream mechanism, but not these specific trial results.
Sermorelin vs CJC-1295: Native Fragment vs Stabilized Analog
Sermorelin is native GHRH(1-29) with a short ~10-12 minute plasma half-life [3]. That brevity motivated longer-acting analogs: a D-Ala2 substitution and the Drug Affinity Complex (DAC) technology behind CJC-1295, where a maleimide group binds serum albumin to extend the half-life over days. Both engage the same GHRH receptor; the difference is duration of action — short-lived native fragment versus albumin-tethered long-acting analog.